Kura Oncology, Inc. (NASDAQ:KURA) Stock Holdings Lifted by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 34.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,060 shares of the company’s stock after acquiring an additional 4,654 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Kura Oncology were worth $372,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Kura Oncology during the 1st quarter valued at $110,000. Cape Investment Advisory Inc. purchased a new position in shares of Kura Oncology during the fourth quarter valued at $176,000. Saxon Interests Inc. acquired a new position in Kura Oncology during the first quarter valued at $201,000. Entropy Technologies LP purchased a new stake in Kura Oncology in the 1st quarter worth about $218,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Kura Oncology by 81.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,617 shares of the company’s stock worth $333,000 after acquiring an additional 7,027 shares during the period.

Kura Oncology Stock Down 2.0 %

KURA stock opened at $19.29 on Friday. The firm has a market cap of $1.47 billion, a PE ratio of -8.89 and a beta of 0.88. Kura Oncology, Inc. has a 1 year low of $7.41 and a 1 year high of $24.17. The company has a fifty day simple moving average of $20.33 and a 200 day simple moving average of $20.66. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The firm’s revenue was up .0% compared to the same quarter last year. During the same period last year, the firm posted ($0.53) earnings per share. Sell-side analysts anticipate that Kura Oncology, Inc. will post -2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on KURA. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Friday, August 9th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Finally, Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $30.60.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.